ADULT Updated: April 23, 2024

Regimen Reference Order – BRST – FEC-100

ARIA: BRST - [FEC-100]

Planned Course: Every 21 days for 6 cycles

Indication for Use: Breast Cancer Adjuvant or Metastatic

CVAD: Preferred (VESICANT INVOLVED)

Proceed with treatment if:

ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$

Contact Physician if parameters not met

Note: Hepatitis B serology results must be reviewed in accordance with CCMB Policy Hepatitis B

Monitoring for Oncology and Hematology Patients

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements				
Drug	Dose	CCMB Administration Guideline		
Instruct patient to start vigo (Self-administered at home	, ,	00 – 900 mL) the morning of cyclophosphamide treatment		

Treatment Regimen – BRST – FEC-100 Establish primary solution 500 mL of: normal saline			
aprepitant	125 mg	Orally 1 hour pre-chemotherapy	
dexamethasone	12 mg	Orally 30 minutes pre-chemotherapy	
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy	
OLANZapine	2.5 mg	Orally 30 minutes pre-chemotherapy	
epiRUBicin	100 mg/m ²	IV Push over 10 to 15 minutes	
fluorouracil	500 mg/m ²	IV Push over 3 to 5 minutes	
cyclophosphamide	500 mg/m ²	IV in normal saline 250 mL over 1 hour	

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

Hepatitis B serology

Hepatitis B surface antigen and Hepatitis B core antibody (drawn within preceding 5 years)

Cardiac monitoring

• Left Ventricular Ejection Fraction (LVEF) monitoring recommended at baseline and as clinically indicated

All Cycles

• CBC, biochemistry, and liver enzymes as per Physician Orders



ADULT BRST – FEC-100

Recommended Support Medications			
Drug	Dose	CCMB Administration Guideline	
aprepitant	80 mg	Orally once daily on Days 2 and 3	
dexamethasone	8 mg	Orally once daily on Days 2, 3 and 4	
OLANzapine	2.5 mg	Orally the evening of Day 1 then twice daily on Days 2, 3 and 4. Also use OLANZapine 2.5 to 5 mg AS NEEDED for breakthrough nausea and vomiting (including Days 1 to 4) up to maximum of 10 mg per day. Contact clinic if nausea/vomiting is not adequately controlled	

DISCHARGE INSTRUCTIONS

- Instruct patient to continue taking anti-emetic(s) at home
- Instruct patient to:
 - o Maintain oral intake of 2000 mL (8 glasses) of fluid daily at home
 - o Empty bladder every 2 hours while awake and at bedtime for 24 hours
 - Obtain immediate assistance as per your clinic's contact instructions if:
 - Symptoms of hemorrhagic cystitis (e.g. dysuria, hematuria)
 - Unable to drink recommended amount of fluid
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- Cumulative anthracycline dose (e.g. epiRUBicin, DOXOrubicin) dose should be calculated. If exceeding recommended lifetime anthracycline dose thresholds and patient is benefiting from ongoing anthracycline therapy, adding dexrazoxane should be considered (see SUPP dexrazoxane)
- Due to the risk of reactivation of Hepatitis B virus (HBV) while on this treatment regimen, prescriber must adhere to CCMB Policy *Hepatitis B Monitoring for Oncology and Hematology Patients* for ordering and interpreting HBV serology and prescribing antiviral prophylaxis

